drugset / Trial / NCT00696072
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
Timeline
- Start
- 2008-08
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | dasatinib anhydrous | Small molecule | 100 mg | Oral |
| Comparator | Letrozole | Other / unclassified | 2.5 mg | Oral |